Abstract YO32
Case summary
Prostatic rhabdomyosarcoma in adult is a uncommon disease of adult. There are few cases reported as adult rhabdomyosarcoma of prostate. Most of the cases present with advanced stage. Modality of treatment vary from that of pediatric counterpart. Moreover stage wise treatment for adult disease are not well defined. We presented a young adult case of rhabdomyosarcoma presented with acute retention of urine and severe lower abdominal pain. After evaluation we thought of prostatic rhabdomyosarcoma which was later confirmed by IHC study. As the case was metastatic during presentation panel of experts recommend neoadjuvant chemotherapy followed by surgery according to the response of the treatment. There is no clear treatment plan recommendation for this advance stage, but we planned to evaluate Doxorubicin and Ifosphamide regimen for clinical trial. Surprisingly the systemic therapy works and after 3 cycle there was a very small residue persist. After almost complete response we recommended to continue further 3 cycle. Though surgery and radiation therapy Is the mainstay of treatment we can recommend neoadjuvant chemotherapy for metastatic rhabdomyosarcoma of prostate in adult from our clinical experience.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract